TEVA Pharmaceutical Industries (NYSE: TEVA) stock: the official figures
TEVA Pharmaceutical Industries (TEVA PHARMACEUTICAL INDUSTRIES LIMITED) is listed on the New York Stock Exchange under the ticker TEVA and belongs to the health care sector. In fiscal 2025 it reported revenue of $17,258m and a net profit of $1,410m, according to the annual accounts it filed with the regulator.
Identifiers for TEVA Pharmaceutical Industries: SEC CIK 818686.
Fiscal 2025 figures
| Item | 2025 | 2024 | Change |
|---|---|---|---|
| Revenue | $17,258m | $16,544m | +4.3% |
| Operating profit | $2,157m | −$303.0m | — |
| Net profit | $1,410m | −$1,639m | — |
| Earnings per share | $1.23 | −$1.45 | — |
| Operating margin | 12.5% | −1.8% | +14.3 pts |
| Net margin | 8.2% | −9.9% | +18.1 pts |
| Total assets | $40,748m | $39,326m | +3.6% |
| Equity | $7,910m | $5,373m | +47.2% |
| Cash | $3,556m | $3,300m | +7.8% |
| Operating cash flow | $1,649m | $1,247m | +32.2% |
Margins are calculated from the filed figures: operating profit and net profit over revenue.
10 fiscal years
| Fiscal year | Revenue | Operating profit | Net profit | Earnings per share | Document |
|---|---|---|---|---|---|
| 2025 | $17,258m | $2,157m | $1,410m | $1.23 | Annual report |
| 2024 | $16,544m | −$303.0m | −$1,639m | −$1.45 | Annual report |
| 2023 | $15,846m | $433.0m | −$559.0m | −$0.50 | Annual report |
| 2022 | $14,925m | −$2,197m | −$2,446m | −$2.20 | Annual report |
| 2021 | $15,878m | $1,716m | $417.0m | $0.38 | Annual report |
| 2020 | $16,659m | −$3,572m | −$3,990m | −$3.64 | Annual report |
| 2019 | $16,887m | −$443.0m | −$999.0m | −$0.91 | Annual report |
| 2018 | $18,271m | −$1,637m | −$2,150m | −$2.35 | Annual report |
| 2017 | $21,853m | −$17,484m | −$16,265m | −$16.26 | Annual report |
| 2016 | $21,903m | $2,154m | $329.0m | $0.07 | Annual report |
The full income statement, balance sheet and cash flow statement are in the annual accounts of TEVA Pharmaceutical Industries. Purchases and sales by its executives and directors are in insider transactions.
Dividends
In fiscal 2018, TEVA Pharmaceutical Industries paid $12.0m in dividends, according to its cash flow statement.
| Fiscal year | Dividends paid | Share of net profit |
|---|---|---|
| 2018 | $12.0m | — |
| 2017 | $901.0m | — |
| 2016 | $1,303m | 396.0% |
Cash paid out as dividends during the fiscal year, including dividends to minority shareholders of subsidiaries when the company does not report them separately. It is not the dividend per share.
Members of Congress who traded TEVA Pharmaceutical Industries
In the congressional reports read up to 9 November 2026, 1 member has disclosed 1 transaction in TEVA Pharmaceutical Industries: Alan Armstrong (1).
Frequently asked questions about TEVA Pharmaceutical Industries
- How much did TEVA Pharmaceutical Industries earn in fiscal 2025?
- TEVA Pharmaceutical Industries reported a net profit of $1,410m for fiscal 2025, on revenue of $17,258m. The year before it reported a net loss of $1,639m.
- What are the earnings per share of TEVA Pharmaceutical Industries?
- They were $1.23 in fiscal 2025, compared with −$1.45 the year before.
- Where is TEVA Pharmaceutical Industries listed?
- TEVA Pharmaceutical Industries is listed on the New York Stock Exchange under the ticker TEVA and belongs to the health care sector.
- Where do the figures for TEVA Pharmaceutical Industries come from?
- From the annual report (Form 10-K) that TEVA Pharmaceutical Industries files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
The annual accounts come from the annual report (Form 10-K) that TEVA Pharmaceutical Industries files with the SEC, the US securities regulator. Each fiscal year in the table links to its filing. Celsmar reads the tagged figures from the document and does not adjust them: if an item is not in the filing, it is not shown. More detail in data sources and, if you spot an error, in corrections. What Celsmar is and what it costs, in its fact sheet.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.